Generate Biomedicines has completed its IPO, raising an impressive $400 million that makes it the largest listing for a biotech on the Nasdaq so far this year. Incubated by investment group Flagship ...
Between now and September, I already have Germany, Boston, Las Vegas, and Italy on the calendar. And while I’m considered an ...
Skip the stress of checked bags with this viral Packing Sudoku method. A travel expert shares how to pack just nine pieces ...
Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...
Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...
Generate:Biomedicines is hoping to raise up to $425 million via a Nasdaq IPO, with the proceeds needed to bankroll its lead antibody through respiratory disease trials. The Flagship Pioneering-founded ...
Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...
The GW Ranch project approved on 8,000 windswept acres of West Texas will look like many of the other data centers that have sprung up across the country to support Silicon Valley’s ambitions for ...
Artificial intelligence company Anthropic announced Wednesday that it will ensure consumer electricity costs remain steady as it expands its data center footprint. Anthropic said it would work with ...
Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results